Richard Preston
Clinical Pharmacology · Miami, FLNPI 1972535011
Payments from drug & device makers
$10,185,949in general payments, 2019–2025
Across 230 payments — averaging $44,287 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$3M
- Vertex$2.4M
- Bristol Myers Squibb$1.5M
- Takeda Pharmaceuticals U.S.A., Inc.$845K
- AbbVie$589K
- Mitsubishi Tanabe Pharma Development America, Inc.$537K
- plus $1.4M from 7 others
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 128 | $2,993,647 |
| Vertex | 5 | $2,383,978 |
| Bristol Myers Squibb | 20 | $1,468,794 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $844,611 |
| AbbVie | 23 | $588,672 |
| Mitsubishi Tanabe Pharma Development America, Inc. | 3 | $536,548 |
| GSK | 4 | $400,863 |
| Immedica Pharma US, Inc. | 7 | $372,404 |
| F. Hoffmann-la Roche AG | 20 | $342,090 |
| Bausch Health US, LLC | 2 | $78,834 |
| Genentech, Inc. | 1 | $74,695 |
| G1 Therapeutics, Inc. | 4 | $71,465 |
| Acacia Pharma Inc | 1 | $29,348 |
How this compares
Too few clinical pharmacology providers in Floridato place this figure against a meaningful peer group, so we don't.
Other clinical pharmacology in Miami
- Kenneth LasseterHialeah$4.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.